Navigation Links
Berg Diagnostics Receives CLIA Certification and Launches Novel Vitamin D Assay
Date:3/1/2012

BOSTON, March 1, 2012 /PRNewswire/ -- Berg Diagnostics, a Boston-based molecular diagnostics company has received Massachusetts Clinical Laboratory Licensure and Certificate of Registration from the Centers for Medicare and Medicaid Services under the Clinical Laboratory Improvement Amendment (CLIA). 

(Logo:  http://photos.prnewswire.com/prnh/20120301/CL62900LOGO )

"The achievement of a CLIA certificate of accreditation informs clients that the laboratory has established a sound foundation of quality and management to assure the accuracy, reliability, and timeliness of patient results," states Mark Kellogg, PhD, MT (ASCP), DABCC, FACB, Associate Director of Chemistry and Director of Laboratory Quality at Children's Hospital Boston, Harvard Medical School.

The CLIA licensure positions the company to enable program designs both for discovery based and clinical diagnostics services acting as fee-for-service, R&D collaborations, and license/royalty agreements where intellectual property could be commercialized under partnership agreements.

"This allows the company to immediately diversify its business operations to clinical biomarker validation, development of companion diagnostics, and other diagnostic assay based designs to gain clinical insight or follow drug or metabolite reactions," said Shen Luan, Co-Founder and COO.

Berg Diagnostics has a unique combination of bioanalytical and omics technology platforms that catalyze pharmacodynamic analyses and monitoring of therapeutic targets and drug products in a high throughput manner.  The combination of cutting-edge instrumentation, a driven ecosystem of innovation with its sister companies, and industry-leading work force allows for excellence in diagnostics development.

"This represents a significant milestone for Berg Diagnostics; it demonstrates the hallmark commitm
'/>"/>

SOURCE Berg Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
2. The butterfly effect in nanotech medical diagnostics
3. Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer
4. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
5. ZyGEM to Provide its Unique DNA and RNA Extraction Technology to Middle East Biomedical Innovator Saudi Diagnostics Ltd.
6. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
7. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
8. Boulder Diagnostics Licenses Novel Rapid Detection Technology for Homocysteine and Related Compounds from Portland State University
9. India In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
10. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
11. Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... & Rockville, MD (PRWEB) August 21, 2014 ... (ITI) is making progress in its development of JRC-LAMP-vax, ... Japanese red cedar pollen. Phase IC studies began this ... real solution to hay fever. , The Japanese red ... 35 million people in Japan. Mountain Cedar pollen wreaks ...
(Date:8/21/2014)... Emmetsburg, IA (PRWEB) August 21, 2014 ... Project LIBERTY Opening , The Court of His Majesty ... King will attend the Grand Opening of POET-DSM Advanced ... on Wednesday, Sept. 3. , The King will take ... formal opening activity, scheduled for 11 a.m.-12:20 p.m. and ...
(Date:8/21/2014)... 21, 2014 OTC Markets Group ... a biotechnology company, on its approval to list ... on OTCQX®, the best marketplace for established U.S. ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... execution of its growth strategy and achievement of ...
(Date:8/21/2014)... St. Louis, MO (PRWEB) August 21, 2014 ... premier, full service biopharmaceutical contract development and manufacturing ... selected by Progenics Pharmaceuticals, Inc., an oncology company ... targeting and treating cancer, to manufacture the anti-prostate ... Progenics’ PSMA ADC product candidate. Under the ...
Breaking Biology Technology:Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... (Amex:,SGN) has announced that the legendary Earvin "Magic" ... ambulatory heart testing with AFL,s,flagship choice, Signalife,s Fidelity ... the greatest basketball superstars of all time, Mr.,Johnson ... multiple,championships from college to the Los Angeles Lakers ...
... September 13, 2007 at the 14th, International Symposium on Hepatitis C ... ... Glasgow, Scotland, VALLEY COTTAGE, New York, September 6 XTL,Biopharmaceuticals ... a late breaker abstract, entitled "Potent Small Molecule HCV,Inhibitors Affecting NS5A-dependent ...
... They,ve gotten the science wrong. They,ve gotten the law wrong. Why ... we trust them ... Coalition for,Lifesaving Cures responded today as opponents of stem cell cures ... weeks. Said Donn Rubin, Chair of Missouri Coalition for Lifesaving ...
Cached Biology Technology:Legendary Earvin 'Magic' Johnson Joins AFL/Signalife Cardiovascular Protection Team 2Legendary Earvin 'Magic' Johnson Joins AFL/Signalife Cardiovascular Protection Team 3XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference 23 strikes, you're out? Refiling of Amendment to Change Constitution to Criminalize Stem Cell Cures Shows Trouble with Anti-Cures Cause 2
(Date:8/22/2014)... to important discoveries in basic and clinical research ... mobilized into a complex offensive spanning multiple fronts. ... chemistry lab could help find new and more ... compound that targets a specific enzyme overexpressed in ... cells from brain tumours. , Chemistry professor Christopher ...
(Date:8/22/2014)... American consumers will finally be able to purchase fuel ... as zero-emissions vehicles, most of the cars will run ... that contributes to global warming. , Now scientists at ... uses an ordinary AAA battery to produce hydrogen by ... through two electrodes that split liquid water into hydrogen ...
(Date:8/21/2014)... , Aug. 21, 2014 Nxt-ID, Inc. ... growing mobile commerce market, announced today that its shares ... stock to be issued in its proposed underwritten public ... for listing on The Nasdaq Capital Market, subject to ... common stock and warrants, and will trade under the ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3
... a paradox that,s puzzled scientists for a half-century. ... depends on those species responding differently to the availability ... species draw a blank? Competitors like black gums ... shaded understories of eastern U.S. forests, yet species-level data ...
... for the study of stem cells and to increase capacity ... initiatives announced today by NIH Director Francis S. Collins, M.D., ... Common Fund, which encourages collaborative research programs across the NIH ... single IC could do alone. The programs are all scheduled ...
... , ... ... ... , ...
Cached Biology News:Forest tree species diversity depends on individual variation 2Forest tree species diversity depends on individual variation 3Emerging science, tech advances highlight new NIH Common Fund programs 2Emerging science, tech advances highlight new NIH Common Fund programs 3Aware, Inc. Joins HIMSS10 Interoperability Showcase to Demonstrate Standards-Based Medical Image Sharing 2Aware, Inc. Joins HIMSS10 Interoperability Showcase to Demonstrate Standards-Based Medical Image Sharing 3Aware, Inc. Joins HIMSS10 Interoperability Showcase to Demonstrate Standards-Based Medical Image Sharing 4Aware, Inc. Joins HIMSS10 Interoperability Showcase to Demonstrate Standards-Based Medical Image Sharing 5Aware, Inc. Joins HIMSS10 Interoperability Showcase to Demonstrate Standards-Based Medical Image Sharing 6
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb...
Request Info...
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
Biology Products: